JPWO2020178282A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020178282A5 JPWO2020178282A5 JP2021552640A JP2021552640A JPWO2020178282A5 JP WO2020178282 A5 JPWO2020178282 A5 JP WO2020178282A5 JP 2021552640 A JP2021552640 A JP 2021552640A JP 2021552640 A JP2021552640 A JP 2021552640A JP WO2020178282 A5 JPWO2020178282 A5 JP WO2020178282A5
- Authority
- JP
- Japan
- Prior art keywords
- prop
- chloro
- pyrazino
- hydroxyphenyl
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004011 3 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000001845 4 membered carbocyclic group Chemical group 0.000 claims description 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- QXNLXOROUHNHEK-MRXNPFEDSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-9-ethynyl-7-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1C#C)F QXNLXOROUHNHEK-MRXNPFEDSA-N 0.000 claims description 3
- 102100030708 GTPase KRas Human genes 0.000 claims description 3
- 102100039788 GTPase NRas Human genes 0.000 claims description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 102200006614 rs104894229 Human genes 0.000 claims description 3
- FDKSHORUCMDCBE-LLVKDONJSA-N (11R)-7-chloro-6-(2-fluoro-6-hydroxyphenyl)-13-prop-2-enoyl-9-oxa-1,5,13-triazatricyclo[9.4.0.03,8]pentadeca-3(8),6-dien-4-one Chemical compound ClC1=C(NC(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)=O)C1=C(C=CC=C1O)F FDKSHORUCMDCBE-LLVKDONJSA-N 0.000 claims description 2
- LBKFXNCTCJUAPJ-GFCCVEGCSA-N (11R)-7-chloro-6-(2-fluoro-6-hydroxyphenyl)-5-methyl-13-prop-2-enoyl-9-oxa-1,5,13-triazatricyclo[9.4.0.03,8]pentadeca-3(8),6-dien-4-one Chemical compound ClC1=C(N(C(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)=O)C)C1=C(C=CC=C1O)F LBKFXNCTCJUAPJ-GFCCVEGCSA-N 0.000 claims description 2
- WTXRIZHWPYILPO-LLVKDONJSA-N (4aR)-7,9-dichloro-8-(2-fluoro-6-hydroxyphenyl)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one Chemical compound ClC=1C(=C(C2=C(C(N3[C@@H](CO2)CN(CC3)C(C=C)=O)=O)C=1)Cl)C1=C(C=CC=C1O)F WTXRIZHWPYILPO-LLVKDONJSA-N 0.000 claims description 2
- WLRNPQLVIGZTHP-OAHLLOKOSA-N (4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-3-prop-2-enoyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepine-9-carbonitrile Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#N)C1=C(C=CC=C1O)Cl WLRNPQLVIGZTHP-OAHLLOKOSA-N 0.000 claims description 2
- HDZROUHWOKROFK-LLVKDONJSA-N (4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-10-hydroxy-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one Chemical compound ClC1=C(C=C(C=2C(N3[C@@H](COC=21)CN(CC3)C(C=C)=O)=O)O)C1=C(C=CC=C1O)F HDZROUHWOKROFK-LLVKDONJSA-N 0.000 claims description 2
- HXXMATDQQRYYQN-CQSZACIVSA-N (4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-3-prop-2-enoyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepine-10-carbonitrile Chemical compound ClC=1C(=CC(=C2CN3[C@@H](COC2=1)CN(CC3)C(C=C)=O)C#N)C1=C(C=CC=C1O)F HXXMATDQQRYYQN-CQSZACIVSA-N 0.000 claims description 2
- VQRNBOAUJWBBGH-OAHLLOKOSA-N (4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-3-prop-2-enoyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepine-9-carbonitrile Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#N)C1=C(C=CC=C1O)F VQRNBOAUJWBBGH-OAHLLOKOSA-N 0.000 claims description 2
- JYWPJYUDJOXMPA-CYBMUJFWSA-N (4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-9-methyl-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one Chemical compound ClC1=C(C(=CC=2C(N3[C@@H](COC=21)CN(CC3)C(C=C)=O)=O)C)C1=C(C=CC=C1O)F JYWPJYUDJOXMPA-CYBMUJFWSA-N 0.000 claims description 2
- QQLJPAAVIPYNJM-QGZVFWFLSA-N (4aR)-7-chloro-8-(2-hydroxy-6-methylphenyl)-3-prop-2-enoyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepine-9-carbonitrile Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#N)C1=C(C=CC=C1C)O QQLJPAAVIPYNJM-QGZVFWFLSA-N 0.000 claims description 2
- FWVAKNWCWBVPKK-CQSZACIVSA-N (4aR)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one Chemical compound ClC1=C(C=CC=2C(N3[C@@H](COC=21)CN(CC3)C(C=C)=O)=O)C1=C2C=NNC2=CC=C1C FWVAKNWCWBVPKK-CQSZACIVSA-N 0.000 claims description 2
- BOJFNACUBIZYFZ-LLVKDONJSA-N (4aR)-7-chloro-9-fluoro-8-(2-fluoro-6-hydroxyphenyl)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one Chemical compound ClC1=C(C(=CC=2C(N3[C@@H](COC=21)CN(CC3)C(C=C)=O)=O)F)C1=C(C=CC=C1O)F BOJFNACUBIZYFZ-LLVKDONJSA-N 0.000 claims description 2
- QOHRESGZAFPFTN-OAHLLOKOSA-N (4aR)-8-(2-chloro-6-hydroxyphenyl)-7-fluoro-3-prop-2-enoyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepine-9-carbonitrile Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1C#N)F QOHRESGZAFPFTN-OAHLLOKOSA-N 0.000 claims description 2
- JNYFZDGABROKLB-HNNXBMFYSA-N (4aS)-7-chloro-6-methyl-8-(5-methyl-1H-indazol-4-yl)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzodiazepin-11-one Chemical compound ClC1=C(C=CC=2C(N3[C@@H](CN(C=21)C)CN(CC3)C(C=C)=O)=O)C1=C2C=NNC2=CC=C1C JNYFZDGABROKLB-HNNXBMFYSA-N 0.000 claims description 2
- LXRIKUVKYZTDOX-AWEZNQCLSA-N (4aS)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-3-prop-2-enoyl-1,2,4,4a,5,6-hexahydropyrazino[2,1-c][1,4]benzodiazepin-11-one Chemical compound ClC1=C(C=CC=2C(N3[C@@H](CNC=21)CN(CC3)C(C=C)=O)=O)C1=C2C=NNC2=CC=C1C LXRIKUVKYZTDOX-AWEZNQCLSA-N 0.000 claims description 2
- FWVAKNWCWBVPKK-AWEZNQCLSA-N (4aS)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one Chemical compound C(C=C)(=O)N1C[C@H]2COC3=C(C(N2CC1)=O)C=CC(=C3Cl)C1=C2C=NNC2=CC=C1C FWVAKNWCWBVPKK-AWEZNQCLSA-N 0.000 claims description 2
- LTAWOYKJBOJKAK-LLVKDONJSA-N 1-[(11R)-4,7-dichloro-6-(2-fluoro-6-hydroxyphenyl)-9-oxa-1,5,13-triazatricyclo[9.4.0.03,8]pentadeca-3(8),4,6-trien-13-yl]prop-2-en-1-one Chemical compound ClC1=NC(=C(C2=C1CN1[C@@H](CO2)CN(CC1)C(C=C)=O)Cl)C1=C(C=CC=C1O)F LTAWOYKJBOJKAK-LLVKDONJSA-N 0.000 claims description 2
- FMNDGABXICBRRK-CQSZACIVSA-N 1-[(11R)-7-chloro-6-(2-chloro-6-hydroxyphenyl)-4-prop-1-ynyl-9-oxa-1,5,13-triazatricyclo[9.4.0.03,8]pentadeca-3,5,7-trien-13-yl]prop-2-en-1-one Chemical compound ClC1=C(N=C(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#CC)C1=C(C=CC=C1O)Cl FMNDGABXICBRRK-CQSZACIVSA-N 0.000 claims description 2
- QSXKFUQZPCMAFG-IBIJPGRPSA-N 1-[(11R)-7-chloro-6-(2-chloro-6-hydroxyphenyl)-5-(trideuteriomethoxy)-9-oxa-1,4,13-triazatricyclo[9.4.0.03,8]pentadeca-3(8),4,6-trien-13-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=NC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)OC([2H])([2H])[2H])C1=C(C=CC=C1O)Cl QSXKFUQZPCMAFG-IBIJPGRPSA-N 0.000 claims description 2
- IEKIKHOMPSASFH-CYBMUJFWSA-N 1-[(11R)-7-chloro-6-(2-chloro-6-hydroxyphenyl)-5-ethynyl-9-oxa-1,4,13-triazatricyclo[9.4.0.03,8]pentadeca-3(8),4,6-trien-13-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=NC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#C)C1=C(C=CC=C1O)Cl IEKIKHOMPSASFH-CYBMUJFWSA-N 0.000 claims description 2
- CRXVWQJGHIYEHY-CYBMUJFWSA-N 1-[(4aR)-7,9-dichloro-8-(2-fluoro-6-hydroxyphenyl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1)Cl)C1=C(C=CC=C1O)F CRXVWQJGHIYEHY-CYBMUJFWSA-N 0.000 claims description 2
- ULYBFBYMMHFCBU-LLVKDONJSA-N 1-[(4aR)-7,9-dichloro-8-(2-fluoro-6-hydroxyphenyl)-10-hydroxy-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1O)Cl)C1=C(C=CC=C1O)F ULYBFBYMMHFCBU-LLVKDONJSA-N 0.000 claims description 2
- UIEKASIZRZVGHP-OAHLLOKOSA-N 1-[(4aR)-7,9-difluoro-8-(2-hydroxy-6-methylphenyl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound FC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1)F)C1=C(C=CC=C1C)O UIEKASIZRZVGHP-OAHLLOKOSA-N 0.000 claims description 2
- HKIMHZZLARGRGN-OAHLLOKOSA-N 1-[(4aR)-7,9-difluoro-8-[2-fluoro-6-(hydroxymethyl)phenyl]-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound FC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1)F)C1=C(C=CC=C1CO)F HKIMHZZLARGRGN-OAHLLOKOSA-N 0.000 claims description 2
- HPHRWQRHJOIBFI-CYBMUJFWSA-N 1-[(4aR)-7,9-difluoro-8-[2-hydroxy-6-(trifluoromethyl)phenyl]-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound FC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1)F)C1=C(C=CC=C1C(F)(F)F)O HPHRWQRHJOIBFI-CYBMUJFWSA-N 0.000 claims description 2
- BHCIYQSAUKPTNJ-GFCCVEGCSA-N 1-[(4aR)-7-chloro-8-(2,3-difluoro-6-hydroxyphenyl)-9-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)F)C1=C(C(=CC=C1O)F)F BHCIYQSAUKPTNJ-GFCCVEGCSA-N 0.000 claims description 2
- DDCOLYFWRBCEPK-LLVKDONJSA-N 1-[(4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-9,10-difluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=C(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)F)F)C1=C(C=CC=C1O)Cl DDCOLYFWRBCEPK-LLVKDONJSA-N 0.000 claims description 2
- QSWCVSXSKPKERJ-MRXNPFEDSA-N 1-[(4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-9-(2-methoxyethoxy)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)OCCOC)C1=C(C=CC=C1O)Cl QSWCVSXSKPKERJ-MRXNPFEDSA-N 0.000 claims description 2
- NWZJRPBBZJDTLS-CYBMUJFWSA-N 1-[(4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-9-(difluoromethoxy)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)OC(F)F)C1=C(C=CC=C1O)Cl NWZJRPBBZJDTLS-CYBMUJFWSA-N 0.000 claims description 2
- FPRHMVHSPSFFKE-MRXNPFEDSA-N 1-[(4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-9-(methoxymethyl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)COC)C1=C(C=CC=C1O)Cl FPRHMVHSPSFFKE-MRXNPFEDSA-N 0.000 claims description 2
- INAQRJCAPCGYHP-MRXNPFEDSA-N 1-[(4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-9-ethynyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#C)C1=C(C=CC=C1O)Cl INAQRJCAPCGYHP-MRXNPFEDSA-N 0.000 claims description 2
- NZDYCPMSAGXVLE-CYBMUJFWSA-N 1-[(4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-9-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)F)C1=C(C=CC=C1O)Cl NZDYCPMSAGXVLE-CYBMUJFWSA-N 0.000 claims description 2
- WACPCGDPHOOOFE-QGZVFWFLSA-N 1-[(4aR)-7-chloro-8-(2-chloro-6-hydroxyphenyl)-9-prop-1-ynyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#CC)C1=C(C=CC=C1O)Cl WACPCGDPHOOOFE-QGZVFWFLSA-N 0.000 claims description 2
- DMCYJIJCULHAMF-OAHLLOKOSA-N 1-[(4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-10-imidazol-1-yl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)N1C=NC=C1)C1=C(C=CC=C1O)F DMCYJIJCULHAMF-OAHLLOKOSA-N 0.000 claims description 2
- YXFXMMFKQJRVMS-CYBMUJFWSA-N 1-[(4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-10-methoxy-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)OC)C1=C(C=CC=C1O)F YXFXMMFKQJRVMS-CYBMUJFWSA-N 0.000 claims description 2
- JDIHBVOUGNFWHI-OAHLLOKOSA-N 1-[(4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-10-pyrazol-1-yl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C=C(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)N1N=CC=C1)C1=C(C=CC=C1O)F JDIHBVOUGNFWHI-OAHLLOKOSA-N 0.000 claims description 2
- AITRFIXHCLHORE-CQSZACIVSA-N 1-[(4aR)-7-chloro-8-(2-fluoro-6-hydroxyphenyl)-9-methoxy-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)OC)C1=C(C=CC=C1O)F AITRFIXHCLHORE-CQSZACIVSA-N 0.000 claims description 2
- HKCSRGQGNGOUGG-MRXNPFEDSA-N 1-[(4aR)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C1=C2C=NNC2=CC=C1C HKCSRGQGNGOUGG-MRXNPFEDSA-N 0.000 claims description 2
- OYJJJJCLXMMCHM-MRXNPFEDSA-N 1-[(4aR)-7-chloro-9-ethynyl-8-(2-fluoro-6-hydroxyphenyl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#C)C1=C(C=CC=C1O)F OYJJJJCLXMMCHM-MRXNPFEDSA-N 0.000 claims description 2
- RYCAFVGOTJZYEW-OAHLLOKOSA-N 1-[(4aR)-7-chloro-9-fluoro-8-(5-methyl-1H-benzimidazol-4-yl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)F)C1=C(C=CC=2NC=NC=21)C RYCAFVGOTJZYEW-OAHLLOKOSA-N 0.000 claims description 2
- UVRQRUSDXDUETH-QGZVFWFLSA-N 1-[(4aR)-7-ethynyl-9-fluoro-8-(2-hydroxy-6-methylphenyl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound C(#C)C1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)F)C1=C(C=CC=C1C)O UVRQRUSDXDUETH-QGZVFWFLSA-N 0.000 claims description 2
- INISFAUXTYWNRF-CYBMUJFWSA-N 1-[(4aR)-8-(2-bromo-6-hydroxyphenyl)-7,9-difluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound BrC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1F)F INISFAUXTYWNRF-CYBMUJFWSA-N 0.000 claims description 2
- ODZXALUNVDIZLX-MRXNPFEDSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-10-[2-(dimethylamino)ethoxy]-7-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C(=C1)OCCN(C)C)F ODZXALUNVDIZLX-MRXNPFEDSA-N 0.000 claims description 2
- CUHVMVHSASDHBD-CYBMUJFWSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-7,9-difluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1F)F CUHVMVHSASDHBD-CYBMUJFWSA-N 0.000 claims description 2
- XYMCHFLTXXOQMK-HXUWFJFHSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-7-fluoro-9-(2-piperidin-1-ylethoxy)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1OCCN1CCCCC1)F XYMCHFLTXXOQMK-HXUWFJFHSA-N 0.000 claims description 2
- NUQPWYJTVLKFMX-LJQANCHMSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-7-fluoro-9-(pyridin-4-ylmethoxy)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1OCC1=CC=NC=C1)F NUQPWYJTVLKFMX-LJQANCHMSA-N 0.000 claims description 2
- CNQOLVBNICGIJB-QGZVFWFLSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-7-fluoro-9-prop-1-ynyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1C#CC)F CNQOLVBNICGIJB-QGZVFWFLSA-N 0.000 claims description 2
- MITPKQJEXXSKPY-CYBMUJFWSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-9-(difluoromethoxy)-7-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1OC(F)F)F MITPKQJEXXSKPY-CYBMUJFWSA-N 0.000 claims description 2
- MHWYYXDJTOKBMG-LJQANCHMSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-9-[3-(dimethylamino)prop-1-ynyl]-7-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1C#CCN(C)C)F MHWYYXDJTOKBMG-LJQANCHMSA-N 0.000 claims description 2
- KPCRHHPIJGMGPW-OAHLLOKOSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-9-cyclopropyloxy-7-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1OC1CC1)F KPCRHHPIJGMGPW-OAHLLOKOSA-N 0.000 claims description 2
- SFXSKORCEGFOFT-CYBMUJFWSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-9-ethynyl-7,10-difluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C(=C1C#C)F)F SFXSKORCEGFOFT-CYBMUJFWSA-N 0.000 claims description 2
- NOPXJJMERVEVRZ-GOSISDBHSA-N 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-9-ethynyl-7-methyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1C#C)C NOPXJJMERVEVRZ-GOSISDBHSA-N 0.000 claims description 2
- LZJHWHGSADWXSG-MRXNPFEDSA-N 1-[(4aR)-8-(2-ethyl-6-hydroxyphenyl)-7,9-difluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound C(C)C1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1F)F LZJHWHGSADWXSG-MRXNPFEDSA-N 0.000 claims description 2
- CWJDPRNPEJUPNS-CYBMUJFWSA-N 1-[(4aR)-8-[2-(difluoromethyl)-6-hydroxyphenyl]-7,9-difluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound FC(C1=C(C(=CC=C1)O)C1=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=C1F)F)F CWJDPRNPEJUPNS-CYBMUJFWSA-N 0.000 claims description 2
- JBVHZQGOFXLOAS-QGZVFWFLSA-N 1-[(4aR)-9-chloro-7-ethynyl-8-(2-hydroxy-6-methylphenyl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1)C#C)C1=C(C=CC=C1C)O JBVHZQGOFXLOAS-QGZVFWFLSA-N 0.000 claims description 2
- VZVIPQOWUWWEID-OAHLLOKOSA-N 1-[(4aR)-9-chloro-7-fluoro-8-(2-hydroxy-6-methylphenyl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1)F)C1=C(C=CC=C1C)O VZVIPQOWUWWEID-OAHLLOKOSA-N 0.000 claims description 2
- MDMIUGMSDNHJTM-CYBMUJFWSA-N 1-[(4aR)-9-chloro-8-(2-chloro-6-hydroxyphenyl)-7-fluoro-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC=1C(=C(C2=C(CN3[C@@H](CO2)CN(CC3)C(C=C)=O)C=1)F)C1=C(C=CC=C1O)Cl MDMIUGMSDNHJTM-CYBMUJFWSA-N 0.000 claims description 2
- HKCSRGQGNGOUGG-INIZCTEOSA-N 1-[(4aS)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one Chemical compound ClC1=C(C=CC=2CN3[C@H](COC=21)CN(CC3)C(C=C)=O)C1=C2C=NNC2=CC=C1C HKCSRGQGNGOUGG-INIZCTEOSA-N 0.000 claims description 2
- SZLCFQUVUMDZRG-CYBMUJFWSA-N 1-[(8R)-12-chloro-13-(2-chloro-6-hydroxyphenyl)-17-methyl-10-oxa-3,6,15,17-tetrazatetracyclo[9.7.0.03,8.014,18]octadeca-1(18),11,13,15-tetraen-6-yl]prop-2-en-1-one Chemical compound ClC1=C(C2=C(C=3CN4[C@@H](COC=31)CN(CC4)C(C=C)=O)N(C=N2)C)C1=C(C=CC=C1O)Cl SZLCFQUVUMDZRG-CYBMUJFWSA-N 0.000 claims description 2
- IZGRYCNCVVWEED-GFCCVEGCSA-N 1-[(8R)-12-chloro-13-(2-fluoro-6-hydroxyphenyl)-10-oxa-3,6,14,16,17-pentazatetracyclo[9.7.0.03,8.014,18]octadeca-1(11),12,15,17-tetraen-6-yl]prop-2-en-1-one Chemical compound ClC1=C(N2C(C=3CN4[C@@H](COC=31)CN(CC4)C(C=C)=O)=NN=C2)C1=C(C=CC=C1O)F IZGRYCNCVVWEED-GFCCVEGCSA-N 0.000 claims description 2
- FNQLJLQPJIJBJT-CYBMUJFWSA-N 1-[(8R)-12-chloro-13-(2-fluoro-6-hydroxyphenyl)-16-methyl-10-oxa-3,6,16,17-tetrazatetracyclo[9.7.0.03,8.014,18]octadeca-1(11),12,14,17-tetraen-6-yl]prop-2-en-1-one Chemical compound ClC1=C(C2=CN(N=C2C2=C1OC[C@@H]1N(C2)CCN(C1)C(C=C)=O)C)C1=C(C=CC=C1O)F FNQLJLQPJIJBJT-CYBMUJFWSA-N 0.000 claims description 2
- SQAQLMHSIWCLKG-CYBMUJFWSA-N 1-[(8R)-12-chloro-13-(2-fluoro-6-hydroxyphenyl)-17-methyl-10-oxa-3,6,16,17-tetrazatetracyclo[9.7.0.03,8.014,18]octadeca-1(18),11,13,15-tetraen-6-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NN(C2=C2C=1OC[C@@H]1N(C2)CCN(C1)C(C=C)=O)C)C1=C(C=CC=C1O)F SQAQLMHSIWCLKG-CYBMUJFWSA-N 0.000 claims description 2
- OOTQNPAYNJJWGP-QGZVFWFLSA-N 8-[(4aR)-7-chloro-9-fluoro-3-prop-2-enoyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-8-yl]-7-methyl-2H-isoquinolin-1-one Chemical compound ClC1=C(C(=CC=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)F)C=1C(=CC=C2C=CNC(C=12)=O)C OOTQNPAYNJJWGP-QGZVFWFLSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 3
- VIQHDHIPTDCHMF-CYBMUJFWSA-N 1-[(11R)-7-chloro-6-(2-chloro-6-hydroxyphenyl)-4-ethynyl-9-oxa-1,5,13-triazatricyclo[9.4.0.03,8]pentadeca-3,5,7-trien-13-yl]prop-2-en-1-one Chemical compound ClC1=C(N=C(C=2CN3[C@@H](COC=21)CN(CC3)C(C=C)=O)C#C)C1=C(C=CC=C1O)Cl VIQHDHIPTDCHMF-CYBMUJFWSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical group N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813885P | 2019-03-05 | 2019-03-05 | |
| US62/813,885 | 2019-03-05 | ||
| US201962951146P | 2019-12-20 | 2019-12-20 | |
| US62/951,146 | 2019-12-20 | ||
| PCT/EP2020/055551 WO2020178282A1 (en) | 2019-03-05 | 2020-03-03 | Fused tricyclic compounds useful as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523981A JP2022523981A (ja) | 2022-04-27 |
| JPWO2020178282A5 true JPWO2020178282A5 (ru) | 2023-02-08 |
| JP7453989B2 JP7453989B2 (ja) | 2024-03-21 |
Family
ID=69740367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552640A Active JP7453989B2 (ja) | 2019-03-05 | 2020-03-03 | 抗癌剤として有用な縮合三環式化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220204527A1 (ru) |
| EP (1) | EP3935060B1 (ru) |
| JP (1) | JP7453989B2 (ru) |
| KR (1) | KR20210135539A (ru) |
| CN (1) | CN113508118B (ru) |
| AU (1) | AU2020231045B2 (ru) |
| BR (1) | BR112021017408A2 (ru) |
| CA (1) | CA3131156A1 (ru) |
| CL (1) | CL2021002296A1 (ru) |
| CO (1) | CO2021012381A2 (ru) |
| CR (1) | CR20210504A (ru) |
| DO (1) | DOP2021000183A (ru) |
| EC (1) | ECSP21073246A (ru) |
| IL (1) | IL285761B1 (ru) |
| JO (1) | JOP20210241A1 (ru) |
| MA (1) | MA55198A (ru) |
| MX (1) | MX2021010674A (ru) |
| PE (1) | PE20220140A1 (ru) |
| SG (1) | SG11202109451TA (ru) |
| TW (1) | TW202100532A (ru) |
| UY (1) | UY38602A (ru) |
| WO (1) | WO2020178282A1 (ru) |
| ZA (1) | ZA202106192B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP4021444A4 (en) | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | G12D KRAS INHIBITORS |
| CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
| JP7340100B2 (ja) | 2019-10-28 | 2023-09-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬 |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN114828964B (zh) | 2019-12-11 | 2023-11-24 | 伊莱利利公司 | Kras g12c抑制剂 |
| CN115135315A (zh) | 2019-12-20 | 2022-09-30 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CN114437107A (zh) * | 2020-11-06 | 2022-05-06 | 江苏先声药业有限公司 | 哌嗪类化合物及其应用 |
| CN114539286B (zh) * | 2020-11-24 | 2024-02-02 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| TW202235082A (zh) | 2020-12-04 | 2022-09-16 | 美商美國禮來大藥廠 | Ｋｒａｓ ｇ１２ｃ抑制劑 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN117083279A (zh) * | 2021-04-08 | 2023-11-17 | 基因泰克公司 | 氧氮杂䓬化合物及其在癌症治疗中的用途 |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| TW202322819A (zh) | 2021-10-22 | 2023-06-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮的四環化合物、其製備方法及其在醫藥上的應用 |
| TW202325298A (zh) * | 2021-11-01 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮的四環化合物、其製備方法及其在醫藥上的應用 |
| CN118434422A (zh) | 2021-12-28 | 2024-08-02 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和rasg12c抑制剂的组合 |
| WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090318412A1 (en) * | 2006-07-11 | 2009-12-24 | Takahiro Matsumoto | Tricyclic heterocyclic compound and use thereof |
| NO2714752T3 (ru) * | 2014-05-08 | 2018-04-21 | ||
| GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| EP3621968A1 (en) | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
-
2020
- 2020-03-03 BR BR112021017408A patent/BR112021017408A2/pt unknown
- 2020-03-03 JO JOP/2021/0241A patent/JOP20210241A1/ar unknown
- 2020-03-03 MA MA055198A patent/MA55198A/fr unknown
- 2020-03-03 KR KR1020217031298A patent/KR20210135539A/ko active Search and Examination
- 2020-03-03 AU AU2020231045A patent/AU2020231045B2/en active Active
- 2020-03-03 JP JP2021552640A patent/JP7453989B2/ja active Active
- 2020-03-03 IL IL285761A patent/IL285761B1/en unknown
- 2020-03-03 PE PE2021001444A patent/PE20220140A1/es unknown
- 2020-03-03 CA CA3131156A patent/CA3131156A1/en active Pending
- 2020-03-03 MX MX2021010674A patent/MX2021010674A/es unknown
- 2020-03-03 SG SG11202109451TA patent/SG11202109451TA/en unknown
- 2020-03-03 WO PCT/EP2020/055551 patent/WO2020178282A1/en unknown
- 2020-03-03 CR CR20210504A patent/CR20210504A/es unknown
- 2020-03-03 US US17/436,137 patent/US20220204527A1/en active Pending
- 2020-03-03 EP EP20708488.0A patent/EP3935060B1/en active Active
- 2020-03-03 CN CN202080018236.1A patent/CN113508118B/zh active Active
- 2020-03-05 UY UY0001038602A patent/UY38602A/es unknown
- 2020-03-05 TW TW109107275A patent/TW202100532A/zh unknown
-
2021
- 2021-08-26 ZA ZA2021/06192A patent/ZA202106192B/en unknown
- 2021-09-01 DO DO2021000183A patent/DOP2021000183A/es unknown
- 2021-09-02 CL CL2021002296A patent/CL2021002296A1/es unknown
- 2021-09-22 CO CONC2021/0012381A patent/CO2021012381A2/es unknown
- 2021-10-01 EC ECSENADI202173246A patent/ECSP21073246A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020178282A5 (ru) | ||
| JP5746172B2 (ja) | ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物 | |
| TW202144338A (zh) | 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用 | |
| KR20240024903A (ko) | 융합된 사환식 화합물, 이에 대한 제조 방법 및 의학에서 이의 적용 | |
| CA3002884A1 (en) | Protein kinase inhibitors, preparation method and medical use thereof | |
| JP7137733B2 (ja) | ｔｏｌｌ様受容体アゴニストとしてのイミダゾ［４，５－Ｃ］ピリジン誘導体 | |
| JP2024519188A (ja) | 含窒素複素環系化合物、その調製方法及びその医薬的応用 | |
| JP2024524262A (ja) | ピリミジンまたはピリジン誘導体およびその製造方法ならびに薬学上の応用 | |
| CN113387962A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| CN117203207A (zh) | 桥环类化合物、其制备方法及其在医药上的应用 | |
| JP2023502458A (ja) | ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 | |
| TW202409047A (zh) | 吡啶并［４，３－ｄ］嘧啶化合物 | |
| WO2022194192A1 (zh) | 一类杂芳环化合物、其制备方法及用途 | |
| JP2001513567A (ja) | カンプトテシン類似体及びその調製方法 | |
| CN116199703A (zh) | 稠合四环杂环化合物、其制备方法及其在医药上的应用 | |
| WO2023143312A1 (zh) | 一种含氮杂环化合物、其制备方法及应用 | |
| CN115368383A (zh) | 稠合含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| CN115385938A (zh) | 苯并嘧啶类化合物、其制备方法及其在医药上的应用 | |
| ES2847229T3 (es) | Compuestos intermedios utilizables en la síntesis de (-)-huperzina y proceso para obtener uno de estos compuestos intermedios | |
| CN113966336A (zh) | 三环类化合物及其用途 | |
| CN118176198A (zh) | 含氮的四环化合物、其制备方法及其在医药上的应用 | |
| WO2021104413A1 (zh) | 稠合吡啶环衍生物、其制备方法及其在医药上的应用 | |
| CA3231988A1 (en) | Azaindazole macrocycle compound and use thereof | |
| CN116143806A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| CN113912608B (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 |